期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 384, 期 -, 页码 133-138出版社
ELSEVIER
DOI: 10.1016/j.jns.2017.11.009
关键词
Antiplatelet therapy; Intracranial hemorrhage; Hematoma expansion; Ischemia; Thromboembolism
资金
- National Natural Science Foundation of China [81771391]
- Chongqing Municipal Public Health Bureau, Chongqing People's Municipal Government [2015ZDXM011]
- Program for Innovative Research Team of Chongqing Kuanren Hospital
Background: Clinical disagreement over antiplatelet (AP) resumption in patients with primary intracranial hemorrhage (ICH) has long existed. This meta-analysis aimed to evaluate the benefits of AP resumption on preventing ischemic or thromboembolic events against its risks of promoting ICH recurrence or hematoma expansion. Methods: All relevant articles published in Pubmed, EMBASE, the Cochrane Library, and Science Direct from January 1950 to March 2017 were sourced, and the combined relative risk (RR) was calculated. Results: A total of 3648 articles were found, and after screening, 6 cohort studies including 1916 patients were included in this meta-analysis. AP resumption was associated with a decreased risk of ischemic or thromboembolic events (RR, 0.61; 95% confidence interval (CI), 0.48-0.79; P < 0.01). There was no significant difference in the risk of ICH recurrence or hematoma expansion between patients with or without AP resumption (RR, 0.84; 95% CI, 0.47-1.51; P = 0.56). Conclusion: AP resumption in patients with primary ICH reduced the risk of ischemic or thromboembolic events, without significant increase of risk of ICH recurrence or hematoma expansion.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据